In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis | Zendy

S. Alvarez | Zendy; M. V. Jones | Zendy; S Holtsclaw-Berk | Zendy; J Guarderas | Zendy; S. L. Berk | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis

Author(s) -

S. Alvarez,

M. V. Jones,

S Holtsclaw-Berk,

J Guarderas,

S. L. Berk

Publication year - 1985

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.27.4.646

Subject(s) - ticarcillin , clavulanic acid , microbiology and biotechnology , cephalosporin , antibiotics , antimicrobial , moraxella (branhamella) catarrhalis , neisseria , beta lactamase , moraxella catarrhalis , biology , bacteria , amoxicillin , haemophilus influenzae , escherichia coli , biochemistry , genetics , gene

We tested 53 clinical isolates of Branhamella catarrhalis recovered from patients with respiratory symptoms to determine the susceptibility of the isolates to 25 antimicrobial agents, including the newer beta-lactam antibiotics. Of the 53 strains, 46 (86.7%) were beta-lactamase producers. All the strains were susceptible to the majority of the new penicillins and cephalosporins. The combinations of amoxacillin-clavulanic acid and ticarcillin-clavulanic acid were also very active against the beta-lactamase-producing strains.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research